Vol. 1 No. 1 (2019): Current Issue
Case Report

A Case of Interstitial Cystitis Associated with the Anti-Programmed- Death-Receptor-1 Inhibitor: Pembrolizumab

Bi-Yun Yu
Department of Respiratory Diseases, Ningbo Medical Center Li Huili Hospital, Zhejiang 315000, China
Xiao-Qi Dong
Department of Respiratory Diseases, Ningbo Medical Center Li Huili Hospital, Zhejiang 315000, China
Di Gui
Department of Respiratory Diseases, Ningbo Medical Center Li Huili Hospital, Zhejiang 315000, China
Chuan Shao
Department of Respiratory Diseases, Ningbo Medical Center Li Huili Hospital, Zhejiang 315000, China
Zhi-Hui Lin
Department of Respiratory Diseases, Ningbo Medical Center Li Huili Hospital, Zhejiang 315000, China
Published December 3, 2019
Keywords
  • Immune checkpoint inhibitors,
  • Immune-related adverse events,
  • Interstitial cystitis

Abstract

Patients treated with antiprogrammed-death-receptor-1inhibitor (PD-1) often experience immune-related Adverse Events (irAEs). Hereby we report a case of nonbacterial interstitial cystitis in advanced NSCLC patient associated with Pembrolizumab before the ninth cycle started. With the use of immunosuppressive steroids, the symptoms disappeared immediately and then tapered gradually. The symptoms recurrent again when the immunotherapy restarted.